Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (November 2024)
21 slides from Senseonics's investor presentation, Nov 19, 2024
Slide 1: Eversense CGM System Corporate Overview November 2024
1 Eversense ® CGM System THE WORLD’S FIRST AND ONLY LONG - TERM CONTINUOUS GLUCOSE MONITORING SYSTEM Corporate Overview November 2024
Slide 2: Forward-Looking Statements
2 FORWARD - LOOKING STATEMENTS Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including st atements regarding managements plans, objectives and goals for future operations, expectations for future financial or other performance, st
Slide 3: Our Mission
3 3 To transform lives in the global diabetes community with differentiated, long - term implantable glucose management technology. OUR MISSION
Slide 4: Senseonics has the first and only fully-implantable CGM lasting one year
4 Senseonics has the first and only fully - implantable continuous glucose monitor (CGM) that lasts for one year The Eversense ® 365 CGM System was recently cleared by the FDA, with commercial launch now underway Addresses the top complaints with other CGMs including comfort, convenience and accurac
Slide 5: Management
5 Timothy Goodnow, PhD President & Chief Executive Officer Mukul Jain, PhD Chief Operating Officer Francine Kaufman, M.D. Chief Medical Officer Rick Sullivan Chief Financial Officer MANAGEMENT
Slide 6: High Growth Market: CGM Fastest Growing Diabetes Technology Segment
6 $5.5 $7.1 $8.1 $9.8 $12.2 $14.8 0 2 4 6 8 10 12 14 2020 2021 2022 2023 2024E 2025E Revenue in Billions ($) HIGH GROWTH MARKET CGM Fastest Growing Diabetes Technology Segment Globally* Estimated U.S. CGM Penetration, ~80% US Type 1 & ~35% US IT ~ 21% CAGR *Estimates for top 4 CGM companies (Dexco
Slide 7: Eversense CGM System Addresses Unmet Needs as the First and Only
7 Therapeutic indication for 18 yo and older. *In the ENHANCE study, Mean Absolute Relative Difference (MARD) of 8.7% was observed in the Eversense® 365 Sensor, and MARD of 9.1% was observed in primary Sensor. See “About Eversense” slide 2 for label and safety information. • CGM that lasts for 12 mo
Slide 8: Strong and Expanding Reimbursement Access
8 STRONG AND EXPANDING REIMBURSEMENT ACCESS FOR OVER 300 MILLION LIVES Recent eligibility expansion extends medicare coverage to all individuals with diabetes who use insulin and non - insulin - taking patients at risk of hypoglycemia Effectively doubling the total addressable patient population. Co
Slide 9: Eversense US Patient Profiles
9 EVERSENSE US PATIENT PROFILES 1 Capturing New Users and Switching Other CGM Users Target patient profiles 1 Senseonics Analysis ² Ascensia internal data Over 3/4 of our US patients switched from other CGM solutions ; 23% New CGM User 77% Switched to Eversense 51% Dexcom 43% Libre 5% Medtronic Type
Slide 10: Commercial Collaboration with Ascensia
10 • Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM • ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense ® 365 and Future Generation Products • Senseonics to Focus Streamlined Operations on Manufacturing, Research and Development
Slide 11: Ascensia Diabetes Care – Senseonics Commercial Partner
11 Ascensia Diabetes Care – Senseonics Commercial Partner Brian Hansen President of CGM for Ascensia Diabetes Care and former Chief Commercial Officer of Tandem Diabetes Three pillars commercial strategy Comprehensive Direct to Consumer Marketing Campaign to Build Awareness Direct - to - Consumer He
Slide 12: Eversense Commercial Launch
12 Eversense 365 Commercial Launch
Slide 13: A Better Solution for Optimal Patient Care
13 A BETTER SOLUTION FOR OPTIMAL PATIENT CARE PATIENTS PROVIDERS Empowering Patients to Live a Life Uninterrupted Enabling Confident Clinical Decisions Longest Lasting CGM The only CGM that lasts for a year, while traditional 10 – 14 - day CGMs often fail early* No More Wasted CGMs Removable smart t
Slide 14: Early Indicators of a Strong Eversense Launch
14 EARLY INDICATORS OF A STRONG EVERSENSE 365 LAUNCH Direct - To - Consumer Leads Eversense 180 Eversense 365 2.3 X 140 direct online BusinessWire reposts, reaching audience of 83 million 7,324 direct press release views on BusinessWire 8 articles in key Diabetes & Consumer Media outlets 12 articles
Slide 15: Hospital System Opportunity Overview
15 HOSPITAL SYSTEM OPPORTUNITY OVERVIEW Market Potential • Over 1,800 Accountable Care Organizations • 400 health systems • ~500,000 hyperglycemic and hypoglycemic events annually resulting in hospitalization cost over $25K per event Multiple Potential Revenue Streams $413B Total Cost of Diabetes In
Slide 16: Health System Solution with Mercy
16 HEALTH SYSTEM SOLUTION WITH MERCY Full Health System Solution • Eversense CGM • Full Year Uninterrupted Data • Enhanced Patient Compliance • Procedure Reimbursement • Eversense RPM • Proactive monitoring and intervention of patients at risk • Reimbursable Services • EON Care • Extended Reach Beyo
Slide 17: Eversense Projected Patient Ramp
17 0.00% 0.10% 0.20% 0.30% 0.40% 0.50% 0.60% 0.70% 0.80% - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 2023 2024 E 2025 E 2026 E 2027 E Patients Market Share Eversense Projected Patient Ramp Today nearly 10M patients utilize CGM Projected Break Even Less than a 1% market share of today’s
Slide 18: Portfolio Overview & Planned Catalysts
18 2028 2027 2026 2025 2024 Eversense ® 365 World’s first one - year sensor Gemini One - year sensor with battery for continuous and optional point - in - time reading Freedom No transmitter included in the System. Direct communication between sensor and handheld PORTFOLIO OVERVIEW & PLANNED CATALYS
Slide 19: Gemini System
19 GEMINI SYSTEM Use Case Target Technology Enhanced ROME2 sensor with integrated battery; updated algorithm Intensively managed patients who want better control + All insulin - using patients + Non - insulin patients Full year use with 1 sensor and 1 cal /week Two unique products: CGM with transmit
Slide 20: Freedom System
20 Enhanced ROME2 sensor with integrated battery and BLE communication ; updated algorithm Intensively managed patients who want better control + All insulin - using patients + Non - insulin patients Use Case Target Technology Full year use with 1 sensor and 1 cal /week No transmitter included in th
Slide 21: Thank You
21 Thank You Corporate Overview November 2024
Senseonics Holdings — Investor Presentation (November 2024) on 6ix